Volume 7, Issue 3 p. 270-279
Featured Article

The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Marilyn S. Albert

Corresponding Author

Marilyn S. Albert

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Corresponding author. Tel.: 410-614-3040; Fax: 410-502-2189.

E-mail address: [email protected]

Search for more papers by this author
Steven T. DeKosky

Steven T. DeKosky

Office of the Dean, University of Virginia, Charlottesville, VA, USA

Department of Neurology, University of Virginia, Charlottesville, VA, USA

Search for more papers by this author
Dennis Dickson

Dennis Dickson

Department of Pathology, Mayo Clinic, Jacksonville, FL, USA

Search for more papers by this author
Bruno Dubois

Bruno Dubois

Institute for Memory and Alzheimer's Disease, INSERM Unit Cognition, Neuro-imagerie et maladies due Cerveau, Groupe Hospitalier Pitie-Salpetriere, Paris, France

Search for more papers by this author
Howard H. Feldman

Howard H. Feldman

Bristol-Myers Squibb Neuroscience, Wallingford, CT, USA

Search for more papers by this author
Nick C. Fox

Nick C. Fox

Institute of Neurology, University College London, London, United Kingdom

Search for more papers by this author
Anthony Gamst

Anthony Gamst

Department of Neuroscience, University of California, San Diego, CA, USA

Search for more papers by this author
David M. Holtzman

David M. Holtzman

Department of Neurology, Washington University, St. Louis, MO, USA

Knight Alzheimer's Disease Research Center, Washington University, St. Louis, MO, USA

Search for more papers by this author
William J. Jagust

William J. Jagust

Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA

Search for more papers by this author
Ronald C. Petersen

Ronald C. Petersen

Department of Neurology, Mayo Clinic, Rochester, MN, USA

Search for more papers by this author
Peter J. Snyder

Peter J. Snyder

Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, USA

Department of Neurology, Alpert Medical School of Brown University, Providence, RI, USA

Search for more papers by this author
Maria C. Carrillo

Maria C. Carrillo

Alzheimer's Association, Chicago, IL, USA

Search for more papers by this author
Bill Thies

Bill Thies

Alzheimer's Association, Chicago, IL, USA

Search for more papers by this author
Creighton H. Phelps

Creighton H. Phelps

National Institute on Aging, Bethesda, MD, USA

Search for more papers by this author
First published: 22 April 2011
Citations: 6,800

Abstract

The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer's disease (AD), referred to in this article as mild cognitive impairment due to AD. The workgroup developed the following two sets of criteria: (1) core clinical criteria that could be used by healthcare providers without access to advanced imaging techniques or cerebrospinal fluid analysis, and (2) research criteria that could be used in clinical research settings, including clinical trials. The second set of criteria incorporate the use of biomarkers based on imaging and cerebrospinal fluid measures. The final set of criteria for mild cognitive impairment due to AD has four levels of certainty, depending on the presence and nature of the biomarker findings. Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings.